Pfizer/BioNTech say data show Covid-19 vaccine safe and protective in kids

The companies said the vaccine generated an immune response in the 5-to-11 year olds in their Phase II/III clinical trial that matched what they had previously observed in 16-to-25 year olds. The safety profile was also generally comparable to the older age group, they said.

Original source: https://health.economictimes.indiatimes.com/news/pharma/pfizer/86368594?utm_source=RSS&utm_medium=ETRSS

Related Posts